‘We have found that from irritable bowel syndrome from irritable bowel syndrome with diarrhea a higher frequency of certain mutations show,’explains Dr. Beate Niesler that examines the genetic causes of complex diseases with her team in the Department of Human Molecular Genetics at the Heidelberg Institute of Human Genetics. These mutations appear to cause changes in the composition or the number of receptors on the cell surface. ‘Signal transduction in the digestive tract may be disturbed and this may lead to overstimulation of the intestine. Resulting disturbances in fluid balance could explain the occurrence of diarrhea,’says Johannes Kapeller, a doctoral student in the team.. Serotonin plays an important role in the complex processes in the digestive tract – as sleep, mood, and affects the blood pressure.

Beate Niesler. The Heidelberg data could contribute to the development and prescription of certain medications for certain genetic mutations in patients.. Medication blocks serotonin receptorsThe serotonin receptor blockers alosetron is only approved in the U.S., where it is effective in the treatment of women suffering from diarrhea – predominant IBS is used, but only with strict limitations due to its side be prescribed effects. Alosetron inhibits the serotonin receptors in the intestinal tract and thus slows the movement of the intestines.Roche Pharma both have a template authorizing the European Medicines Agency on Herceptin made as adjuvant therapy in HER2-positive cancer 17 February 2006. NICE may not indicative the NHS on Last drugs until they who were licensed.. University of North Carolina at Chapel Hill School of Medicine, 101 Manning Dr in Chapel Hill 6 002 the East Wing.

Takes place 2nd licensing through the medicines and Healthcare products Regulatory Agency performed associated with European Medicines Agency .

Important issues financed by Breast Cancer Trials supply rather positives.

The importance of our trial is non saying that the pharmaceutical industry is anything wrong it makes outstanding in the development of of new therapies, and there are lots latest examples in breast cancer research , but as more and more research is funded by drug companies. Then the limited funds from external sources to on address to other any questions, Peppercorn said.

Other articles from category "therapy":

Random articles